GCG and Stroke: In 33 GLP1-RAs trials (1,637 strokes, 70,443 participants), GLP1-RAs use did decrease stroke risk significantly (RR: 0.84, 95% CI [0.77, 0.93], p = 0.0005) vs. non-GLP1-RAs use (Supplementary Figures S7, S8).